MX2022012384A - COMPOSITIONS AND METHODS TO SCREEN MUTATIONS IN THYROID CANCER. - Google Patents

COMPOSITIONS AND METHODS TO SCREEN MUTATIONS IN THYROID CANCER.

Info

Publication number
MX2022012384A
MX2022012384A MX2022012384A MX2022012384A MX2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A
Authority
MX
Mexico
Prior art keywords
methods
thyroid cancer
compositions
patient
thyroid
Prior art date
Application number
MX2022012384A
Other languages
Spanish (es)
Inventor
Kevin Qu
Joseph J Catanese
Andrew Grupe
Feras Hantash
Frederic M Waldman
Shih-Min Cheng
Original Assignee
Quest Diagnostics Invest Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Llc filed Critical Quest Diagnostics Invest Llc
Publication of MX2022012384A publication Critical patent/MX2022012384A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La presente tecnología se refiere a métodos para determinar si un paciente que tiene nódulos tiroideos con citología indeterminada se beneficiará de una cirugía diagnostica, por ejemplo, lobectomía. Estos métodos se basan en el cribado de los nódulos tiroideos de un paciente y la detección de alteraciones en las secuencias de ácido nucleicos diana que corresponden a una serie específica de genes relacionados con el cáncer de tiroides. También se proveen kits para usarse en la práctica de los métodos.The present technology relates to methods of determining whether a patient who has thyroid nodules with indeterminate cytology will benefit from diagnostic surgery, for example, lobectomy. These methods are based on screening a patient's thyroid nodules and detecting alterations in target nucleic acid sequences that correspond to a specific set of genes related to thyroid cancer. Kits are also provided to use in practicing the methods.

MX2022012384A 2015-12-31 2018-06-29 COMPOSITIONS AND METHODS TO SCREEN MUTATIONS IN THYROID CANCER. MX2022012384A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562273783P 2015-12-31 2015-12-31
US201662439572P 2016-12-28 2016-12-28

Publications (1)

Publication Number Publication Date
MX2022012384A true MX2022012384A (en) 2023-01-16

Family

ID=59225391

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008197A MX2018008197A (en) 2015-12-31 2016-12-30 Compositions and methods for screening mutations in thyroid cancer.
MX2022012384A MX2022012384A (en) 2015-12-31 2018-06-29 COMPOSITIONS AND METHODS TO SCREEN MUTATIONS IN THYROID CANCER.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018008197A MX2018008197A (en) 2015-12-31 2016-12-30 Compositions and methods for screening mutations in thyroid cancer.

Country Status (5)

Country Link
US (2) US11053542B2 (en)
EP (2) EP3397766B1 (en)
CN (1) CN108699553B (en)
MX (2) MX2018008197A (en)
WO (1) WO2017117523A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109371139A (en) * 2018-12-29 2019-02-22 杭州迪安医学检验中心有限公司 A kind of primer and its application being used to detect the variation of thyroid cancer pathogenic related gene based on high throughput sequencing technologies
CN109652535A (en) * 2019-01-30 2019-04-19 上海安甲生物科技有限公司 Identify human thyroid tubercle good pernicious kit and its application method and application
US20210010060A1 (en) * 2019-07-02 2021-01-14 Genenius Genetics Highly Multiplexed PCR with Bioinformatically Optimized Primers to Prepare Targeted Libraries for Next-Generation Sequencing
CN110241215B (en) * 2019-07-03 2020-05-19 上海润安医学科技有限公司 Primer and kit for detecting benign and malignant genetic variation of thyroid nodule
CA3153646A1 (en) * 2019-07-19 2021-01-28 Quest Diagnostics Investments Llc Methods for detecting hereditary cancers
IT201900024009A1 (en) * 2019-12-13 2021-06-13 Univ Degli Studi Roma La Sapienza NEW PROCEDURE FOR THE DIAGNOSIS OF A THYROID CANCER AND RELATED KIT
CN110878358B (en) * 2019-12-19 2020-08-25 上海宝藤生物医药科技股份有限公司 Thyroid cancer markers and application thereof
CN112080566B (en) * 2020-08-25 2021-08-17 上海交通大学医学院附属瑞金医院 Thyroid cancer detection products and uses based on high-throughput sequencing
CN112011615A (en) * 2020-09-01 2020-12-01 上海睿璟生物科技有限公司 Gene fusion kit for human thyroid cancer and detection method
CN111979327A (en) * 2020-09-01 2020-11-24 上海睿璟生物科技有限公司 Detection kit and detection method for human thyroid gland extraction-free oncogene mutation
CN114277115A (en) * 2020-09-27 2022-04-05 上海鹍远生物科技股份有限公司 Thyroid nodule benign and malignant related marker and application thereof
CN114807350A (en) * 2022-05-09 2022-07-29 上海睿璟生物科技有限公司 Biomarker for judging benign and malignant thyroid nodules, polygene joint inspection kit and application
CN117286247A (en) * 2022-09-07 2023-12-26 上海医创云康生物科技有限公司 Thyroid gene detection kit
CN117821596B (en) * 2024-02-20 2024-06-28 上海睿璟生物科技有限公司 NGS detection method for high-sensitivity auxiliary diagnosis of benign and malignant thyroid nodules
CN119265304B (en) * 2024-11-13 2025-10-17 广州达健生物科技有限公司 Composition for thyroid cancer detection, kit and application

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795762A (en) 1986-08-22 1998-08-18 Roche Molecular Systems, Inc. 5' to 3' exonuclease mutations of thermostable DNA polymerases
US5466591A (en) 1986-08-22 1995-11-14 Hoffmann-La Roche Inc. 5' to 3' exonuclease mutations of thermostable DNA polymerases
WO1992006188A2 (en) 1990-10-05 1992-04-16 Barnes Wayne M Thermostable dna polymerase
US20080312093A1 (en) * 2005-11-04 2008-12-18 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
CA2557134A1 (en) * 2006-08-23 2008-02-23 National Research Council Of Canada Molecular method for diagnosis of colon cancer
KR101656543B1 (en) * 2009-03-13 2016-09-09 가부시키가이샤 야쿠르트 혼샤 Method for determining sensitivity to irinotecan and use thereof
US8980554B2 (en) * 2010-07-26 2015-03-17 The Johns Hopkins University Genetic make-up modifies cancer outcome
GB201017011D0 (en) * 2010-10-08 2010-11-24 Skova Services Ltd Assay
EP2505664B1 (en) * 2011-03-30 2014-12-03 Universität Leipzig Method and means for distinguishing malignant from benign tumor samples, in particular in routine air dried fine needle aspiration biopsy (FNAB)
US20130142728A1 (en) * 2011-10-27 2013-06-06 Asuragen, Inc. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
CN103088433B (en) * 2011-11-02 2014-09-24 深圳华大基因科技服务有限公司 Construction method and application of genome-wide methylation high-throughput sequencing library
US10077474B2 (en) 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
AU2013352339B2 (en) * 2012-11-27 2019-07-04 Pontificia Universidad Catolica De Chile Compositions and methods for diagnosing thyroid tumors
WO2014152822A2 (en) * 2013-03-14 2014-09-25 Quest Diagnostics Investments Incorporated Method for detecting cystic fibrosis
WO2014160834A1 (en) * 2013-03-27 2014-10-02 The Johns Hopkins University Tert promoter mutations in cancer
WO2015024075A1 (en) * 2013-08-23 2015-02-26 Agriculture Victoria Services Pty Ltd Method of nucleic acid fragmentation
WO2015038190A1 (en) * 2013-09-13 2015-03-19 Life Technologies Corporation Classification and actionability indices for cancer
WO2015153808A1 (en) * 2014-04-01 2015-10-08 The Johns Hopkins University Tert and braf mutations in human cancer
CN105200134A (en) * 2015-09-18 2015-12-30 杭州泛生子医学检验所有限公司 Method and kit for detecting human TERT gene promoter mutation
CN108315424B (en) * 2018-04-10 2021-08-06 广东省人民医院(广东省医学科学院) PCR-specific primers, detection kits and detection methods for benign and malignant related genes of thyroid nodules

Also Published As

Publication number Publication date
EP4246144A3 (en) 2023-12-20
EP3397766A4 (en) 2019-10-02
US20210324468A1 (en) 2021-10-21
US11053542B2 (en) 2021-07-06
CA3010013A1 (en) 2017-07-06
EP3397766B1 (en) 2023-05-17
EP4246144A2 (en) 2023-09-20
CN108699553A (en) 2018-10-23
US20190112653A1 (en) 2019-04-18
BR112018013430A2 (en) 2018-12-18
CN108699553B (en) 2023-08-04
WO2017117523A1 (en) 2017-07-06
EP3397766A1 (en) 2018-11-07
US12516372B2 (en) 2026-01-06
MX2018008197A (en) 2019-02-20

Similar Documents

Publication Publication Date Title
MX2022012384A (en) COMPOSITIONS AND METHODS TO SCREEN MUTATIONS IN THYROID CANCER.
CL2021000716A1 (en) Antibody constructs for flt3 and cd3. (divisional sol. 201800269)
CO2017011238A2 (en) Humanized anti-c1s antibodies
MX2022007933A (en) Polymethine compounds and their use as fluorescent labels.
CU24533B1 (en) ANTIBODIES OR FRAGMENTS THEREOF THAT BIND THYMIC STROMAL LYMPHOPOYETIN (TSLP) AND PHARMACEUTICAL COMPOSITIONS THEREOF
CL2019000975A1 (en) Anti-c1s antibodies and methods of using them
BR112018074468A2 (en) anti-cd40 antibodies and their uses
CL2017001328A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
CL2017003069A1 (en) Methods to diagnose and treat cancer.
BR112016013347A2 (en) anti-il-33 neutralizing human monoclonal antibody
EA201792497A1 (en) ANTIBODIES TO GITR FOR DIAGNOSIS OF MALIGNANT TUMOR
BR112017020893A2 (en) method for cancer treatment
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
EA201692157A1 (en) SYNTHESIS OF TWO-CELLULAR NUCLEIC ACIDS
WO2015119941A3 (en) Genome fractioning
CO2017011546A2 (en) Acrylic emulsion adhesives
HK1246828A1 (en) Biomarker panel for the detection of cancer
MX2016012479A (en) MEMBERS OF UNION TO THE TUMOR NECROSIS FACTOR (TNF) ALPHA.
MX2023002379A (en) MULTIVALENT AND MULTI-SPECIFIC DR5-BINDING FUSION PROTEINS.
UY36200A (en) SET OF SPECIFIC BIOMARKERS FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER
MX2017008096A (en) Pestivirus.
MX2016013849A (en) A PROTEIN SECRETION FACTOR WITH HIGH EFFECTIVENESS SECRETORA AND AN EXPRESSION VECTOR THAT UNDERSTANDS IT.
MX381948B (en) COMPOSITIONS AND METHODS FOR DETERMINING THE PROGNOSIS OF ENDOMETRIAL CANCER.
EA202091497A2 (en) GENETIC LOCUS ASSOCIATED WITH INCREASED FERTILITY IN MAIS
MX2018013222A (en) Interferon beta antibodies and uses thereof.